Skip to main navigation

Investors

News Archive
Past Events and Presentations
Stock History

News Archive

News Archive

Items Per Page

Year

Nov 08, 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Nov 03, 2016

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

Nov 02, 2016

Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)

Oct 26, 2016

Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets

Oct 20, 2016

Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Oct 07, 2016

Mylan Agrees to Settlement on Medicaid Rebate Classification for EpiPen® Auto-Injector

Sep 30, 2016

Mylan Launches Generic Fortamet® Tablets

Sep 01, 2016

Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding

Aug 29, 2016

Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product

Aug 25, 2016

Mylan Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrine Injection, USP) Auto-Injector

Pagination

First page
Previous page
…
Page 21
Page 22
Page 23
Page 24
Current page 25
Page 26
Page 27
Page 28
Page 29
…
Next page
Last page

Share

Utility Nav

Privacy Statement
Terms and Conditions

©2025 Mylan N.V. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.